PTO/SB/81 (01-09)

Approved for use through 11/30/2011. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 10067895 POWER OF ATTORNEY Filing Date 2002-02-05 OR Thomas Kruse Hansen First Named Inventor **REVOCATION OF POWER OF ATTORNEY** Compounds with Growth Hormone Releasing Pro Title WITH A NEW POWER OF ATTORNEY Art Unit AND **Examiner Name** CHANGE OF CORRESPONDENCE ADDRESS 25245.13 Attorney Docket Number

I hereby revoke all previous powers of attorney given in the above-identified application.							
	orney is submitted herewith.						
I hereby appoint Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith:				53,449			
OR I hereby appoint Practitioner(s) named below as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith:							
	Practitioner(s) Name		Registration Number				
				,		<u>-</u>	
Please recognize or change the correspondence address for the above-identified application to:							
The address associated with the above-mentioned Customer Number.							
OR							
The address associated with Customer Number: OR							
Firm or Individual Name							
Address							
City			State		Zip		
Country							
Telephone			Email				
	or. ord of the entire interest. See 37 CFR : r 37 CFRy3:¶3(b) (Form PTO/SB/96) s		or filed on _				
SIGNATURE of Applicant or Assignee of Record							
Signature	J. Marie			Date	03/10/10		
Name	Franco De Vecchi			Telephone	908.203.6550		
Title and Company Chairman & President - Helsinn Therapeutics (U.S.), Inc.							
NOTE: Signatures of all the inventors or assignces of record of the entire Interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.							
*Total offorms are submitted.							

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)						
Applicant/Patent Owner: Helsinn Therapeutics (U.S.), Inc.						
Application No./Patent No.: 10/067,895	Filed/Issue Date: February 5, 2002					
Titled: Compounds with Growth Hormone Releasing Prope	erties					
Helsinn Therapeutics (U.S.), Inc. , a corpo	oration					
(Name of Assignee) (Typ	e of Assignee, e.g., corporation, partnership, university, government agency, etc.					
states that it is:						
1. X the assignee of the entire right, title, and interest in;						
2. an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is%); or						
3. the assignee of an undivided interest in the entirety of (a	a complete assignment from one of the joint inventors was made)					
the patent application/patent identified above, by virtue of either:						
the United States Patent and Trademark Office at Reel	ation/patent identified above. The assignment was recorded in, Frame, or for which a					
copy therefore is attached. OR						
B. X A chain of title from the inventor(s), of the patent applica	ation/patent identified above, to the current assignee as follows:					
1. From: Thomas Kruse Hansen et al.	To: Novo Nordisk A/S					
The document was recorded in the United St	ates Patent and Trademark Office at					
Reel 008492 , Frame 0829	or for which a copy thereof is attached.					
2. From: Novo Nordisk A/S	To: Sapphire Therapeutics					
The document was recorded in the United States Patent and Trademark Office at						
Reel 022277 Frame 0160	or for which a copy thereof is attached.					
3. From: Sapphire Therapeutics, Inc.	To: Helsinn Therapeutics US, Inc.					
The document was recorded in the United States Patent and Trademark Office at						
Reel 023778 , Frame 0301	, or for which a copy thereof is attached.					
Additional documents in the chain of title are listed on						
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence or concurrently is being, submitted for recordation pursuant	ence of the chain of title from the original owner to the assignee was, to 37 CFR 3.11.					
accordance with 37 GFR Part 3, to record the assignment in						
The undersigned (whose title is supplied below) is authorized to ac	t on behalf of the assignee.					
Signature						
Franco De Vecchi	Chairman & President					
Printed or Typed Name	Title					

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.